In hematological malignancies, PTEN promoter was found hypermethylated in 20% of acute lymphoblastic leukemia and chronic myeloid leukemia cases, and it is also involved in the mechanism determining imatinib resistance [17]. This evidence concerns the gene PTEN and acute lymphoblastic leukemia.